Stereotaxis Q2 revenue $9.1M (+70% YoY); sees system revenue doubling in 2022

Stereotaxis, Inc.

2021-Q2 EPS reported -$0.05 revenue$17,673,980

Revenue up ~70% YoY to $9.1M; system revenue $2.7M, recurring $6.1M.
Operating loss $3.4M, net loss $1.2M; adjusted net income $1.6M excluding stock comp.
Cash $44.2M; free cash flow negative $0.1M vs negative $1.2M prior year.
Received two robotic system orders (U.S. and Beijing); expects ~$11M system revenue in 2021.
Guidance: system revenue doubling in 2022; magnetic ablation catheter regulatory submissions in early 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.